Stay updated on Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.7%
    Check dated 2025-06-20T05:56:18.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.2 to version 2.16.3.
    Difference
    0.1%
    Check dated 2025-06-13T00:49:23.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The page has updated the revision number from v2.16.1 to v2.16.2, and the previous publication of the KEYNOTE-087 study has been removed, which included an erratum notice.
    Difference
    0.3%
    Check dated 2025-06-05T20:46:16.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-29T15:24:02.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-05-01T02:21:47.000Z thumbnail image
  7. Check
    76 days ago
    Change Detected
    Summary
    The page has been updated to include new information about Hodgkin Lymphoma and a new registry identifier, while significant details about the clinical trial and its criteria have been removed.
    Difference
    11%
    Check dated 2025-04-16T14:20:04.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Relapsed Hodgkin Lymphoma Clinical Trial page.